192 related articles for article (PubMed ID: 12029096)
1. Identification of X-linked inhibitor of apoptosis-associated factor-1 as an interferon-stimulated gene that augments TRAIL Apo2L-induced apoptosis.
Leaman DW; Chawla-Sarkar M; Vyas K; Reheman M; Tamai K; Toji S; Borden EC
J Biol Chem; 2002 Aug; 277(32):28504-11. PubMed ID: 12029096
[TBL] [Abstract][Full Text] [Related]
2. IFN-beta pretreatment sensitizes human melanoma cells to TRAIL/Apo2 ligand-induced apoptosis.
Chawla-Sarkar M; Leaman DW; Jacobs BS; Borden EC
J Immunol; 2002 Jul; 169(2):847-55. PubMed ID: 12097388
[TBL] [Abstract][Full Text] [Related]
3. X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO).
Ng CP; Bonavida B
Mol Cancer Ther; 2002 Oct; 1(12):1051-8. PubMed ID: 12481428
[TBL] [Abstract][Full Text] [Related]
4. Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines.
Chawla-Sarkar M; Leaman DW; Borden EC
Clin Cancer Res; 2001 Jun; 7(6):1821-31. PubMed ID: 11410525
[TBL] [Abstract][Full Text] [Related]
5. Silencing of the XAF1 gene by promoter hypermethylation in cancer cells and reactivation to TRAIL-sensitization by IFN-beta.
Micali OC; Cheung HH; Plenchette S; Hurley SL; Liston P; LaCasse EC; Korneluk RG
BMC Cancer; 2007 Mar; 7():52. PubMed ID: 17376236
[TBL] [Abstract][Full Text] [Related]
6. Expression of RASSF1A, an epigenetically silenced tumor suppressor, overcomes resistance to apoptosis induction by interferons.
Reu FJ; Leaman DW; Maitra RR; Bae SI; Cherkassky L; Fox MW; Rempinski DR; Beaulieu N; MacLeod AR; Borden EC
Cancer Res; 2006 Mar; 66(5):2785-93. PubMed ID: 16510600
[TBL] [Abstract][Full Text] [Related]
7. Novel growth and death related interferon-stimulated genes (ISGs) in melanoma: greater potency of IFN-beta compared with IFN-alpha2.
Leaman DW; Chawla-Sarkar M; Jacobs B; Vyas K; Sun Y; Ozdemir A; Yi T; Williams BR; Borden EC
J Interferon Cytokine Res; 2003 Dec; 23(12):745-56. PubMed ID: 14769151
[TBL] [Abstract][Full Text] [Related]
8. Apo2L/TRAIL induction and nuclear translocation of inositol hexakisphosphate kinase 2 during IFN-beta-induced apoptosis in ovarian carcinoma.
Morrison BH; Tang Z; Jacobs BS; Bauer JA; Lindner DJ
Biochem J; 2005 Jan; 385(Pt 2):595-603. PubMed ID: 15634191
[TBL] [Abstract][Full Text] [Related]
9. Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells.
Zhang XD; Franco AV; Nguyen T; Gray CP; Hersey P
J Immunol; 2000 Apr; 164(8):3961-70. PubMed ID: 10754286
[TBL] [Abstract][Full Text] [Related]
10. Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells.
Poulaki V; Mitsiades CS; Kotoula V; Tseleni-Balafouta S; Ashkenazi A; Koutras DA; Mitsiades N
Am J Pathol; 2002 Aug; 161(2):643-54. PubMed ID: 12163389
[TBL] [Abstract][Full Text] [Related]
11. Variable expression of protein kinase C epsilon in human melanoma cells regulates sensitivity to TRAIL-induced apoptosis.
Gillespie S; Zhang XD; Hersey P
Mol Cancer Ther; 2005 Apr; 4(4):668-76. PubMed ID: 15827341
[TBL] [Abstract][Full Text] [Related]
12. Cell Death Inhibiting RNA (CDIR) modulates IFN-gamma-stimulated sensitization to Fas/CD95/Apo-1 and TRAIL/Apo-2L-induced apoptosis.
Shchors K; Yehiely F; Deiss LP
Cell Cycle; 2004 Dec; 3(12):1606-11. PubMed ID: 15611657
[TBL] [Abstract][Full Text] [Related]
13. An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis.
Kim Y; Suh N; Sporn M; Reed JC
J Biol Chem; 2002 Jun; 277(25):22320-9. PubMed ID: 11940602
[TBL] [Abstract][Full Text] [Related]
14. The involvement of TNF-alpha-related apoptosis-inducing ligand in the enhanced cytotoxicity of IFN-beta-stimulated human dendritic cells to tumor cells.
Liu S; Yu Y; Zhang M; Wang W; Cao X
J Immunol; 2001 May; 166(9):5407-15. PubMed ID: 11313377
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis.
Evdokiou A; Bouralexis S; Atkins GJ; Chai F; Hay S; Clayer M; Findlay DM
Int J Cancer; 2002 Jun; 99(4):491-504. PubMed ID: 11992538
[TBL] [Abstract][Full Text] [Related]
16. Resistance and susceptibility of human uveal melanoma cells to TRAIL-induced apoptosis.
Li H; Niederkorn JY; Neelam S; Alizadeh H
Arch Ophthalmol; 2005 May; 123(5):654-61. PubMed ID: 15883285
[TBL] [Abstract][Full Text] [Related]
17. Promotion of TRAIL/Apo2L-induced apoptosis by low-dose interferon-β in human malignant melanoma cells.
Kazaana A; Sano E; Yoshimura S; Makita K; Hara H; Yoshino A; Ueda T
J Cell Physiol; 2019 Aug; 234(8):13510-13524. PubMed ID: 30613977
[TBL] [Abstract][Full Text] [Related]
18. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria.
Zhang XD; Zhang XY; Gray CP; Nguyen T; Hersey P
Cancer Res; 2001 Oct; 61(19):7339-48. PubMed ID: 11585775
[TBL] [Abstract][Full Text] [Related]
19. Stat1-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand and the cell-surface death signaling pathway by interferon beta in human cancer cells.
Choi EA; Lei H; Maron DJ; Wilson JM; Barsoum J; Fraker DL; El-Deiry WS; Spitz FR
Cancer Res; 2003 Sep; 63(17):5299-307. PubMed ID: 14500361
[TBL] [Abstract][Full Text] [Related]
20. Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL.
Bae SI; Cheriyath V; Jacobs BS; Reu FJ; Borden EC
Oncogene; 2008 Jan; 27(4):490-8. PubMed ID: 17653094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
